• 1. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
• 4. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 5. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143

URACIL mixture with TEGAFUR (4:1) (CAS No. 74578-38-4)

The URACIL mixture with TEGAFUR (4:1), identified by the CAS No. 74578-38-4, is a well-established compound in the field of oncology and pharmacology. This mixture is composed of uracil and tegafur in a 4:1 ratio, designed to enhance the therapeutic efficacy and reduce the side effects associated with chemotherapy. The combination of these two compounds has been extensively studied and has shown promising results in various clinical trials.

Uracil is a pyrimidine base that plays a crucial role in RNA synthesis and is also involved in DNA repair mechanisms. In the context of cancer treatment, uracil has been found to modulate the metabolism of fluoropyrimidines, such as 5-fluorouracil (5-FU), which is a widely used antineoplastic agent. By inhibiting the catabolism of 5-FU, uracil can potentiate its cytotoxic effects on tumor cells, thereby improving treatment outcomes.

Tegafur, on the other hand, is a prodrug of 5-FU. It is metabolized in the liver to produce 5-FU, which then exerts its antitumor activity by inhibiting thymidylate synthase, an enzyme essential for DNA synthesis. The inclusion of tegafur in this mixture ensures a sustained release of 5-FU, which can lead to better drug exposure and reduced toxicity compared to administering 5-FU alone.

The URACIL mixture with TEGAFUR (4:1) has been evaluated in numerous preclinical and clinical studies. One notable study published in the *Journal of Clinical Oncology* demonstrated that this combination significantly improved overall survival and progression-free survival in patients with advanced colorectal cancer compared to standard 5-FU therapy. The study also reported a favorable safety profile, with fewer severe adverse events observed in the treatment group.

Recent advancements in pharmacogenomics have further enhanced our understanding of how genetic variations can influence the efficacy and toxicity of this mixture. For instance, polymorphisms in genes involved in uracil and tegafur metabolism, such as *DPYD* and *UGT1A1*, have been identified as potential biomarkers for predicting treatment response and adverse effects. This knowledge has paved the way for personalized medicine approaches, where patients can be stratified based on their genetic profiles to optimize treatment outcomes.

In addition to its use in colorectal cancer, the URACIL mixture with TEGAFUR (4:1) has shown promise in other solid tumors, including gastric cancer and breast cancer. A phase II trial conducted in patients with advanced gastric cancer reported a high response rate and manageable toxicity profile, suggesting that this mixture could be a valuable addition to the therapeutic arsenal for this disease.

The mechanism of action of this mixture involves multiple pathways. Uracil's ability to inhibit dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for breaking down 5-FU, leads to increased intratumoral levels of 5-FU. This enhanced concentration of 5-FU results in more effective inhibition of thymidylate synthase and subsequent disruption of DNA synthesis in cancer cells. Tegafur's prodrug nature ensures a steady supply of 5-FU over an extended period, which can help maintain therapeutic levels and minimize fluctuations that might otherwise lead to resistance or toxicity.

Clinical trials have also explored the use of this mixture in combination with other anticancer agents to achieve synergistic effects. For example, combining URACIL mixture with TEGAFUR (4:1) with oxaliplatin or irinotecan has shown enhanced antitumor activity and improved patient outcomes in several studies. These findings highlight the potential for this mixture to be integrated into multidrug regimens for more effective cancer treatment.

In conclusion, the URACIL mixture with TEGAFUR (4:1) (CAS No. 74578-38-4) represents a significant advancement in oncology therapy. Its unique composition and mechanism of action offer several advantages over traditional chemotherapy agents, including improved efficacy, reduced toxicity, and potential for personalized medicine approaches. Ongoing research continues to uncover new insights into its therapeutic potential, making it an important tool in the fight against various types of cancer.

• 17902-23-7(Tegafur)
• 50-91-9(Floxuridine)
• 1189456-27-6(TEGAFUR-13C,15N2)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)